- Roche's Columvi (RHHBY, Financial) shows a 40% improvement in overall survival for DLBCL patients.
- 89% of complete responders remain alive one year post-treatment.
- Columvi is approved in over 30 countries for non-transplant-eligible DLBCL patients.
Roche (RHHBY) has published promising two-year follow-up data for its Columvi® treatment, in combination with chemotherapy, for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The phase III STARGLO study demonstrates a 40% improvement in overall survival compared to the standard treatment, offering renewed hope for patients with this aggressive form of lymphoma.
A closer look at the study's data reveals that 89% of complete responders were alive one year after treatment, while 82% maintained remission during the same period. Notably, the study reported a 58.5% complete remission rate, significantly higher than the 25.3% observed in the control group. The risk of disease progression or death was reduced by 59% with the Columvi regimen.
The Columvi combination is now approved in over 30 countries for DLBCL patients who are not candidates for autologous stem cell transplant. While the treatment's safety profile aligns with previous findings, it includes a higher rate of adverse events, such as cytokine release syndrome, which is common but generally low-grade.
The combination therapy has also been incorporated into the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 1 preferred recommendation for second-line DLBCL treatment for those not proceeding to transplant. The updated results solidify Columvi's status as a potentially transformative option in the treatment landscape for patients with limited alternatives.
